Validation of GPR65 as a Novel Immuno-oncology Target using Advanced In Vitro & In Vivo Models
Time: 4:30 pm
day: Day One PM
Details:
- Identification of GPR65 as a novel immuno-oncology target as well as potent GPR65 inhibitors
- Provide additional validation using primary tumorhistocultures and genetically engineered mice
- Advancing biomarker development to accelerate clinical development
